Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market to Reach $278 Million by 2030
The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$153 Million in the year 2022, is projected to reach a revised size of US$278 Million by 2030, growing at a CAGR of 7.7% over the analysis period 2022-2030. Collagen, one of the segments analyzed in the report, is projected to record a 7.5% CAGR and reach US$158.8 Million by the end of the analysis period. Growth in the Hyaluronic Acid segment is estimated at 6.9% CAGR for the next 8-year period.
The Autologous Matrix-Induced Chondrogenesis (AMIC) market is poised for growth due to the increasing prevalence of joint disorders. Despite a global economic update, the pandemic has cast a shadow over the normalcy of orthopedic surgery volumes. The market share of key competitors in the AMIC sector in 2023 reflects a competitive landscape, with various players exhibiting strong, active, niche, or trivial market presence. Recent market activity underscores ongoing developments and adaptations within the AMIC market to address evolving needs and challenges in orthopedic care.
The U.S. Market is Estimated at $49.5 Million, While China is Forecast to Grow at 9.8% CAGR
The Autologous Matrix-Induced Chondrogenesis (AMIC) market in the U.S. is estimated at US$49.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$26.1 Million by the year 2030 trailing a CAGR of 9.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 7.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 214 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $153 Million |
| Forecasted Market Value (USD) by 2030 | $278 Million |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
MARKET TRENDS & DRIVERS
- AMIC Holds Significance in Cartilage Repair Domain
- Rise in Sports Participation and Increase in Sports-Related Injuries Augment Growth Prospects
- Autologous Matrix-Induced Chondrogenesis (AMIC) in Ankle Repair: A Review
- Growing Demand for Minimally-Invasive Surgeries to Propel Market Growth
- Rise in Incidence of Osteoporosis to Benefit Market Growth
- AMIC: Highly Effective in Management of Focal Chondral Defects of the Knee
- Assessment of Open & Arthroscopic Approaches for AMIC to Repair Cartilage Defects
- Cellular Therapy as Lifeblood of Clinical Routines Targeting Cartilage Regeneration
- MACI Solutions: Promising Options in Articular Cartilage Treatment
- Aging Population and their Vulnerability to Various Bone and Joint Related Diseases and Disorders Drive Healthy Market Growth
- Rise in Overweight Patients to Boost Prospects
- Changing Lifestyle Impacting Bone Health
- Rising Healthcare Spending Augurs Well for the Market
FOCUS ON SELECT PLAYERS(Total 28 Featured)
- Anika Therapeutics, Inc.
- Arthro Kinetics AG
- B. Braun Melsungen AG
- BioTissue SA
- CartiHeal, Inc.
- Geistlich Pharma AG
- JRI Orthopaedics Ltd.
- Matricel GmbH
- Smith & Nephew PLC
- Zimmer Biomet Holdings, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/mgyj9f
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
